Danaher acquired Beckman Coulter for $83.50/share (~$6.8B enterprise value), announced February 7, 2011 and closed June 30, 2011, folding Beckman's clinical-diagnostics and life-science platforms into Danaher's Life Sciences & Diagnostics segment.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedFeb 07, 2011
ClosedJun 30, 2011
Deal value$6.8B
Deal typeAcquisition/Merger
Therapeutic areaClinical diagnostics, life-science research
IndicationsClinical diagnostics, life-science research
Key assetsDiagnostic instruments and life-science research platforms